GPE
Novartis Announces 139 Layoffs in New Jersey Amid Ongoing Restructuring Efforts
Novartis, layoffs, New Jersey, restructuring, pharmaceutical industry
Acadia Pharmaceuticals Secures Exclusive Licensing Deal for Saniona’s Tremor Treatment Asset Worth Up to $582 Million
Acadia Pharmaceuticals, Saniona, tremor treatment, licensing deal, biobucks, neurological disorder
Novartis Announces 139 Job Cuts in New Jersey Amid Commercial Refocus
Novartis, job cuts, New Jersey, commercial refocus, restructuring
Acadia Pharmaceuticals Secures Exclusive License for SAN711, a Novel Essential Tremor Treatment
Acadia Pharmaceuticals, SAN711, Essential Tremor, Licensing Agreement, Saniona, GABAA-α3 Positive Allosteric Modulator
Bristol Myers Squibb Announces Additional Layoffs in New Jersey Amid Cost-Cutting Efforts
Bristol Myers Squibb, layoffs, New Jersey, cost-cutting, pharmaceutical industry
Grifols Rejects Brookfield’s €6.45 Billion Takeover Bid, Citing Undervaluation
Grifols, Brookfield, takeover offer, undervaluation, private equity
Bayer Secures Exclusive Rights to Aficamten in Japan Through Licensing Agreement with Cytokinetics
Bayer, Cytokinetics, Aficamten, Japan, Licensing Agreement, Hypertrophic Cardiomyopathy (HCM), Cardiac Myosin Inhibitor
Breakthrough in Heart Disease Treatment: Lilly’s Muvalaplin and Silence Therapeutics’ Zerlasiran Show Promising Results in Lowering Lipoprotein(a) Levels
Lipoprotein(a) (Lp(a)), Heart Disease, Muvalaplin, Zerlasiran, Cardiovascular Risk, Gene Silencing Therapy, RNA Interference, Atherosclerotic Cardiovascular Disease
Lilly’s Muvalaplin Shows Promising Results in Reducing Lipoprotein(a) Levels in Adults at High Risk for Cardiovascular Events
Muvalaplin, Lipoprotein(a) [Lp(a)], Cardiovascular risk, Oral drug, Phase II trial, Eli Lilly, Cholesterol reduction
CSL Behring Closes California R&D Site, Shifts Operations to Massachusetts Amid Strategic Repositioning
CSL Behring, California R&D site closure, gene therapy, ex vivo work, strategic repositioning, Massachusetts relocation